Sung Jean C, Pulliam Brian L, Edwards David A
Harvard School of Engineering and Applied Sciences, 40 Oxford Street, ESL 406, Cambridge, MA 02138, USA.
Trends Biotechnol. 2007 Dec;25(12):563-70. doi: 10.1016/j.tibtech.2007.09.005. Epub 2007 Nov 8.
The lungs are an attractive route for non-invasive drug delivery with advantages for both systemic and local applications. Incorporating therapeutics with polymeric nanoparticles offers additional degrees of manipulation for delivery systems, providing sustained release and the ability to target specific cells and organs. However, nanoparticle delivery to the lungs has many challenges including formulation instability due to particle-particle interactions and poor delivery efficiency due to exhalation of low-inertia nanoparticles. Thus, novel methods formulating nanoparticles into the form of micron-scale dry powders have been developed. These carrier particles exhibit improved handling and delivery, while releasing nanoparticles upon deposition in the lungs. This review covers the development of nanoparticle formulations for pulmonary delivery as both individual nanoparticles and encapsulated within carrier particles.
肺是无创药物递送的一个有吸引力的途径,对全身和局部应用都有优势。将治疗药物与聚合物纳米颗粒结合为递送系统提供了更多的操控维度,可实现持续释放以及靶向特定细胞和器官的能力。然而,纳米颗粒递送至肺部存在诸多挑战,包括由于颗粒间相互作用导致的制剂不稳定性,以及由于低惯性纳米颗粒呼出导致的递送效率低下。因此,已开发出将纳米颗粒制成微米级干粉形式的新方法。这些载体颗粒在处理和递送方面表现更佳,同时在肺部沉积时会释放纳米颗粒。本综述涵盖了用于肺部递送的纳米颗粒制剂的发展,包括单独的纳米颗粒以及封装在载体颗粒内的纳米颗粒。